An experimental medication could provide the first drug option for treating urinary stress incontinence TAS-303 reduced the frequency of leaks related to stress incontinence compared with placebo About 65% of women taking TAS-303 had the frequency of leaks drop by more than half MONDAY, July 15, 2024 (HealthDay News) -- An experimental drug appears to help women deal with stress incontinence, clinical trial data show. The drug, for now dubbed TAS-303, reduced the frequency of leaks related to stress incontinence by about 58%, compared with 47% reduction in a placebo group, trial results show. Further, about 65% of patients taking TAS-303 had their stress incontinence episodes drop by at least half, compared with 53% of patients who got a placebo, researchers said.
" adds new evidence that TAS-303 reduces the frequency of incontinence episodes in women with SUI," researcher with Chukyo Hospital, in Nagoya, Japan, said in a news release. TAS-303 is in a class of medications called highly selective noradrenaline reuptake inhibitors. These drugs typically are used to treat mental disorders like depression and ADHD.
However, prior research has shown that these drugs also can act to prevent stress incontinence by increasing pressure within the urethra, researchers noted. Stress incontinence involves urine leakage when a person is exerting themselves or sneezing or coughing. It’s a common problem in women, who can develop stress incontinence as a result of pregnancy, childbirth or.
